medmix Future Growth

Future criteria checks 4/6

medmix is forecast to grow earnings and revenue by 60.5% and 7.2% per annum respectively. EPS is expected to grow by 60.5% per annum. Return on equity is forecast to be 13.2% in 3 years.

Key information

60.5%

Earnings growth rate

60.5%

EPS growth rate

Medical Equipment earnings growth	14.3%
Revenue growth rate	7.2%
Future return on equity	13.2%
Analyst coverage	Low
Last updated	04 Mar 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

SWX:MEDX - Analysts future estimates and past financials data (CHF Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	605	70	N/A	N/A	1
12/31/2025	563	52	41	N/A	2
12/31/2024	521	34	50	N/A	1
12/31/2023	487	0	3	56	N/A
9/30/2023	481	5	-3	47	N/A
6/30/2023	475	10	-9	37	N/A
3/31/2023	476	11	0	42	N/A
12/31/2022	477	12	9	48	N/A
9/30/2022	478	21	22	57	N/A
6/30/2022	480	31	36	66	N/A
3/31/2022	468	37	46	76	N/A
12/31/2021	457	44	55	87	N/A
9/30/2021	435	36	56	90	N/A
6/30/2021	414	28	57	94	N/A
3/31/2021	382	19	32	72	N/A
12/31/2020	351	10	8	51	N/A
12/31/2019	421	25	53	89	N/A
12/31/2018	454	52	64	94	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MEDX's forecast earnings growth (60.5% per year) is above the savings rate (0.2%).

Earnings vs Market: MEDX's earnings (60.5% per year) are forecast to grow faster than the Swiss market (8% per year).

High Growth Earnings: MEDX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: MEDX's revenue (7.2% per year) is forecast to grow faster than the Swiss market (4.3% per year).

High Growth Revenue: MEDX's revenue (7.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MEDX's Return on Equity is forecast to be low in 3 years time (13.2%).

medmix Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 24%, revenue upgraded

Consensus EPS estimates fall by 26%

Price target decreased by 10% to CHF30.50

Consensus EPS estimates fall by 19%

Price target increased by 13% to CHF34.00

Consensus EPS estimates fall by 25%

Recent updates

Upcoming dividend of CHF0.50 per share

Consensus EPS estimates fall by 24%, revenue upgraded

New minor risk - Earnings quality

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 20% overvalued

Consensus EPS estimates fall by 26%

Price target decreased by 10% to CHF30.50

New minor risk - Financial data availability

medmix AG, Annual General Meeting, Apr 24, 2024

Consensus EPS estimates fall by 19%

medmix (VTX:MEDX) Is Reinvesting At Lower Rates Of Return

An Intrinsic Calculation For medmix AG (VTX:MEDX) Suggests It's 21% Undervalued

Now 20% undervalued after recent price drop

Price target increased by 13% to CHF34.00

Investors Could Be Concerned With medmix's (VTX:MEDX) Returns On Capital

Consensus EPS estimates fall by 25%

First half 2023 earnings released: EPS: CHF0.18 (vs CHF0.23 in 1H 2022)

medmix AG (SWX:MEDX) completed the acquisition of 70% stake in Guangdong Qiaoyi Plastic Co. LTD.

Upcoming dividend of CHF0.50 per share at 2.3% yield

Consensus EPS estimates increase by 17%

Price target decreased by 12% to CHF30.00

There May Be Reason For Hope In medmix's (VTX:MEDX) Disappointing Earnings

Full year 2022 earnings released: EPS: CHF0.28 (vs CHF1.07 in FY 2021)

Consensus EPS estimates fall by 12%

Consensus forecasts updated

Consensus forecasts updated

medmix (VTX:MEDX) May Have Issues Allocating Its Capital

medmix AG (SWX:MEDX) agreed to acquire unknown majority stake in Guangdong Qiaoyi Plastic Co. LTD.

Medmix AG agreed to acquire plastics business of Universal de Suministros, S.L., Spain.

First half 2022 earnings released: EPS: CHF0.58 (vs CHF0.55 in 1H 2021)

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 13%

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors